Start date: 
Ecraid STRIDE-CAP

STRIDE-CAP Full Study

70 Sites
4 Countries
0 Participants

The STRIDE-CAP Full Study is an international, multi-centre, observational study designed to evaluate the real-world effectiveness of the adult-specific pneumococcal conjugate vaccine, V116 (CAPVAXIVE™). 

This study follows the successful completion of the STRIDE-CAP Pilot in 2025, which validated the operational approach and feasibility of the large-scale rollout.

 

Study Overview

  • Design: International, observational, test-negative design (TND) case-control study
  • Objective: To evaluate the vaccine effectiveness of V116 within a real-world clinical context
  • Recruitment Target: 9,900 participants in Europe
  • Duration: Recruitment is scheduled from Q3 2026 to Q1 2029

 

Ecraid’s Role & Operational Scope

Ecraid is responsible for the operational management and site selection across the European region.

Leveraging its clinical network (CLIN-Net), Ecraid ensures high-quality data collection and standardised study execution across diverse healthcare systems.

 

  • Site Selection: Identification and qualification of 70 clinical sites
  • Geographic Reach: The study is concentrated in four European countries: Austria, France, Italy, and Spain
  • Management: Full oversight of European site performance and recruitment milestones

 

Collaboration & Funding

This study is a collaborative effort between industry and clinical research leaders to generate robust real-world evidence for public health.

  • Sponsor (EU) & Funder: Merck Sharpe & Dohme LLC
  • Global CRO: IQVIA
  • Clinical Management (Europe): Ecraid

 

From Pilot to Full Study

The transition from the STRIDE-CAP Pilot to the Full Study was informed by a rigorous assessment of recruitment strategies and data flow. 

The Pilot provided the necessary evidence to scale the study to its current target of 22,000 participants worldwide (of which 9,900 in Europe).

 

Technical Insights

For details on the improvements and methodological refinements derived from the pilot phase, the Pilot Results Summary is coming soon!